Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2016-04-27
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in
different ways. Some block the ability of tumor cells to grow and spread. Others find tumor
cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop
the growth of tumor cells by blocking blood flow to the tumor. Hydroxychloroquine may help
chemotherapy and bevacizumab work better and kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving hydroxychloroquine together with
capecitabine, oxaliplatin, and bevacizumab works in treating patients with metastatic
colorectal cancer.